GLP-1

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

News

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.

News

Closed Loop Medicine has launched its first product in the US, a digital tool for personalising the dose of GLP-1 weight-loss therapies.

News

Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.